Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention
- PMID: 23747760
- DOI: 10.1016/j.jacc.2013.05.029
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention
Abstract
Objectives: The purpose of this study was to investigate the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimens in atrial fibrillation (AF) patients after myocardial infarction (MI) or percutaneous coronary intervention (PCI).
Background: The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications.
Methods: A total of 12,165 AF patients hospitalized with MI and/or undergoing PCI between 2001 and 2009 were identified by nationwide registries (60.7% male; mean age 75.6 years). Risk of MI/coronary death, ischemic stroke, and bleeding according to antithrombotic treatment regimen was estimated by Cox regression models.
Results: Within 1 year, MI or coronary death, ischemic stroke, and bleeding events occurred in 2,255 patients (18.5%), 680 (5.6%), and 769 (6.3%), respectively. Relative to triple therapy (oral anticoagulation [OAC] plus aspirin plus clopidogrel), no increased risk of recurrent coronary events was seen for OAC plus clopidogrel (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.48 to 1.00), OAC plus aspirin (HR: 0.96, 95% CI: 0.77 to 1.19), or aspirin plus clopidogrel (HR: 1.17, 95% CI: 0.96 to 1.42), but aspirin plus clopidogrel was associated with a higher risk of ischemic stroke (HR: 1.50, 95% CI: 1.03 to 2.20). Also, OAC plus aspirin and aspirin plus clopidogrel were associated with a significant increased risk of all-cause death (HR: 1.52, 95% CI: 1.17 to 1.99 and HR: 1.60, 95% CI: 1.25 to 2.05, respectively). When compared to triple therapy, bleeding risk was nonsignificantly lower for OAC plus clopidogrel (HR: 0.78, 95% CI: 0.55 to 1.12) and significantly lower for OAC plus aspirin and aspirin plus clopidogrel.
Conclusions: In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.
Keywords: AF; ATC; Anatomical Therapeutical Chemical; CI; HR; ICD; International Classification of Diseases; MI; OAC; PCI; antithrombotic treatment; atrial fibrillation; bleeding; confidence interval; hazard ratio; myocardial infarction; oral anticoagulant; percutaneous coronary intervention; stroke.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Antithrombotic regimens in patients with atrial fibrillation and coronary disease: optimizing efficacy and safety.J Am Coll Cardiol. 2013 Sep 10;62(11):990-1. doi: 10.1016/j.jacc.2013.04.072. Epub 2013 Jun 7. J Am Coll Cardiol. 2013. PMID: 23747772 No abstract available.
-
Reply: A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct answer?J Am Coll Cardiol. 2014 Jul 15;64(2):231-2. doi: 10.1016/j.jacc.2013.11.049. Epub 2014 Feb 5. J Am Coll Cardiol. 2014. PMID: 24509278 No abstract available.
-
A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct answer?J Am Coll Cardiol. 2014 Jul 15;64(2):231. doi: 10.1016/j.jacc.2013.10.089. Epub 2014 Feb 5. J Am Coll Cardiol. 2014. PMID: 24509279 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
